We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mineralys Therapeutics Inc | NASDAQ:MLYS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.28 | 2.30% | 12.43 | 11.88 | 16.30 | 12.53 | 11.9731 | 12.08 | 152,939 | 01:00:00 |
From Jul 2023 to Jul 2024
| Stifel Healthcare Conference: | |
| Date: | Wednesday, November 15, 2023 |
| Time: | 12:40pm EST |
| Format: | Fireside Chat |
| Jefferies London Healthcare Conference: | |
| Date: | Thursday, November 16, 2023 |
| Time: | 10:30am GMT |
| Format: | Corporate Presentation |
| Webcast: | Link |
| Evercore ISI 6th Annual HealthCONx Conference: | |
| Date: | Wednesday, November 29, 2023 |
| Time: | 11:15am EST |
| Format: | Fireside Chat |
| Webcast: | Link |
A live webcast of the presentation and fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.
About Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:Investor Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir Health Public RelationsPhone: (1) 515-707-9678Email: tweible@elixirhealthpr.com
1 Year Mineralys Therapeutics Chart |
1 Month Mineralys Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
